Journal Watch · Frontiers in Immunology · 2026

Efficacy and safety of combining radiotherapy with first-line chemotherapy and immunotherapy for local advanced/metastatic urothelial cancer: a propensity score matching analysis.

Liver metastases, radiotherapy, and better treatment response were independently associated with OS.<h4>Conclusions</h4>The addition of radiotherapy to first-line immunotherapy and chemotherapy demonstrated favorable clinical activity and an acceptable safety profile in patients with la/mUC.

Qin J, Zhou H, Li X et al.Frontiers in Immunology3 min readPharma relevance 85/100

DOI: 10.3389/fimmu.2026.1786952PMID: 42488678Study type: cohort / observational clinical study

TL;DR

Liver metastases, radiotherapy, and better treatment response were independently associated with OS.<h4>Conclusions</h4>The addition of radiotherapy to first-line immunotherapy and chemotherapy demonstrated favorable clinical activity and an acceptable safety profile in patients with la/mUC.

Key findings

  • 13.53 months), the difference did not reach statistical significance (<i>P</i> = 0.385).
  • Radiation-related enteritis and cystitis were observed in the ICRT group, while no treatment-related deaths occurred.
  • Multivariate Cox regression analysis identified lung metastases, elevated C-reactive protein levels, radiotherapy, and treatment response exceeding stable disease as independent predictors of PFS.
  • Liver metastases, radiotherapy, and better treatment response were independently associated with OS.<h4>Conclusions</h4>The addition of radiotherapy to first-line immunotherapy and chemotherapy demonstrated favorable clinical activity and an acceptable safety profile in patients with la/mUC.

Numbers at a glance (from the abstract)

n = 31n = 73

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

7.93 months; <i>P</i> = 0.002) and OS (38.9 vs. 19.8 months; <i>P</i> = 0.031) compared with the ICT group. The ICRT cohort demonstrated higher PFS, OS, and ORR across all evaluated time points, with statistically significant differences at 6-month PFS, 12-month PFS, and 12-month OS (<i>P</i> < 0.05). Although the median DOR was numerically longer in the ICRT group (29.23 vs.

Full abstract (original)

Background: <h4>Aim</h4>This study evaluates the effectiveness and safety of combining radiotherapy with first-line chemotherapy and immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).<h4>Methods</h4>This retrospective study included patients with la/mUC who received first-line systemic treatment between January 2017 and December 2024. Two treatment strategies were compared: immunotherapy combined with chemotherapy followed by radiotherapy (ICRT group, n = 31) and immunotherapy combined with chemotherapy alone (ICT group, n = 73). Propensity score matching was used to reduce confounding and selection bias, yielding 30 matched patient pairs. Clinical endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events.<h4>Results</h4>After propensity score matching, the ICRT group showed significantly prolonged PFS (18.70 vs.

What they did: 7.93 months; <i>P</i> = 0.002) and OS (38.9 vs. 19.8 months; <i>P</i> = 0.031) compared with the ICT group. The ICRT cohort demonstrated higher PFS, OS, and ORR across all evaluated time points, with statistically significant differences at 6-month PFS, 12-month PFS, and 12-month OS (<i>P</i> < 0.05). Although the median DOR was numerically longer in the ICRT group (29.23 vs.

Results & conclusions: 13.53 months), the difference did not reach statistical significance (<i>P</i> = 0.385). Radiation-related enteritis and cystitis were observed in the ICRT group, while no treatment-related deaths occurred. Multivariate Cox regression analysis identified lung metastases, elevated C-reactive protein levels, radiotherapy, and treatment response exceeding stable disease as independent predictors of PFS. Liver metastases, radiotherapy, and better treatment response were independently associated with OS.<h4>Conclusions</h4>The addition of radiotherapy to first-line immunotherapy and chemotherapy demonstrated favorable clinical activity and an acceptable safety profile in patients with la/mUC.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1786952 · PubMed 42488678.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

Liver metastases, radiotherapy, and better treatment response were independently associated with OS.<h4>Conclusions</h4>The addition of radiotherapy to first-line immunotherapy and chemotherapy demonstrated favorable clinical activity and an acceptable safety profile in patients with la/mUC.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. 7.93 months; <i>P</i> = 0.002) and OS (38.9 vs.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1786952. PubMed ID: 42488678. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Qin J, Zhou H, Li X et al.. Efficacy and safety of combining radiotherapy with first-line chemotherapy and immunotherapy for local advanced/metastatic urothelial cancer: a propensity score matching analysis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1786952.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/efficacy-and-safety-of-combining-radiotherapy-with-first-line-chemothera-786952/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides